| |
Thursday, March 21, 2024 | 11am ET / 8am PT Join us for a discussion on the evolution of HCP engagement through the lens of Customer Science – the integration of data science, behavioral science, and AI. In this webinar, we explore how Customer Science brings substantial benefits to commercial leaders, providing a deeper understanding of HCPs and patients for more effective engagement. Register now.
|
|
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Register now and SAVE $300 until February 23 to take your TMF to the next level. Sign up today!
|
|
| By Annalee Armstrong,Gabrielle Masson More biotech companies filed for bankruptcy in 2023 than any year since 2010, underscoring a brutal year defined by layoffs, company closures and pipeline reprioritizations. |
|
|
|
By Annalee Armstrong AI drug hunter Exscientia has fired CEO Andrew Hopkins effective immediately after the board determined he had engaged in two personal relationships with employees that were deemed “inappropriate and inconsistent” with company values. |
By Nick Paul Taylor Pfizer has touched down at the Super Bowl. The Big Pharma ran its “Here’s to Science” ad at the event, framing its work to “outdo cancer” as part of a history of breakthroughs dating back to Hippocrates. |
By Max Bayer Roche is laying off employees within its product development team, with the total reductions slated to impact less than 6% of full-time employees in the unit. The pharma group reported 7% growth in its non-COVID business. |
By Angus Liu Takeda's Eohilia has surprisingly won over the FDA even after the company had at one point abandoned the program following an FDA rejection. But the first FDA-approved oral eosinophilic esophagitis therapy comes with a limitation. |
By Angus Liu Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. Department of Justice is looking into the company’s foreign operations. |
By Annalee Armstrong Gilead is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay Therapeutics, specifically for the primary biliary cholangitis med seladelpar. |
By Andrea Park The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. |
By Fraiser Kansteiner Despite some turbulence at Catalent, including an 11% sales drop for the quarter, investors still seem to be buzzed about the stock after this week’s announcement that Novo Holdings is buying out the CDMO for $16.5 billion. |
By Helen Floersh A new discovery might offer some answers about why allergies happen—as well as open up a potential role for approved biologic drugs like Dupixent or Xolair. |
By Kevin Dunleavy The FDA has slapped Piramal with a Form 483 write-up, citing three observations from an inspection conducted from Jan. 29 to Feb. 6 at its active pharmaceutical ingredient (API) plant in Riverview, Michigan. |
Fierce podcastsDon’t miss an episode |
| | This week on "Podnosis," Fierce Healthcare's Paige Minemyer, Dave Muoio and Noah Tong share insights into this year's Fierce 15, discussing the companies that made the cut and the important issues they're addressing. |
|
|---|
|
|
| WhitepaperSupercharge Your Field Deployment in 2024 with Engaging, Clinically-Oriented and Influential FRMs, MSLs, NAMs and CNEs. Krista Pinto, President, Field Deployment, EVERSANA |
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
